source
- Galderma receives FDA complete response letter for anti-wrinkle neuromodulatorGalderma has been issued a complete response letter by the U.S. Food and Drug Administration for its experimental anti-wrinkle product relabotulinumtoxinA, which was under review as a neuromodulato…
- BrightGene advances obesity drug toward Chinese approval, eyes Western data and partnersBrightGene has submitted its obesity GLP-1 candidate to Chinese regulators after reporting strong Phase 3 results. The company says data from Western trials are expected to be even more robust, wh…